Strange: Bullish IOVA Analysts Actually See -3.4% Downside
January 11, 2021 at 09:01 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Iovance Biotherapeutics Inc (IOVA). The average 12-month price target for IOVA — averaging the work of 10 analysts — reveals an average price target of $48.80/share..